4-Phenyl-7-Azaindoles as Potent, Selective and Bioavailable Ikk2 Inhibitors Demonstrating Good in Vivo Efficacy.
Liddle, J., Bamborough, P., Barker, M.D., Campos, S., Chung, C., Cousins, R.P.C., Faulder, P., Heathcote, M.L., Hobbs, H., Holmes, D.S., Ioannou, C., Ramirez-Molina, C., Morse, M.A., Osborn, R., Payne, J.J., Pritchard, J.M., Rumsey, W.L., Tape, D.T., Vicentini, G., Whitworth, C., Williamson, R.A.(2012) Bioorg Med Chem Lett 22: 5222
- PubMed: 22801646 
- DOI: https://doi.org/10.1016/j.bmcl.2012.06.065
- Primary Citation of Related Structures:  
4AWI - PubMed Abstract: 
The lead optimization of a series of potent azaindole IKK2 inhibitors is described. Optimization of the human whole blood activity and selectivity over IKK1 in parallel led to the discovery of 16, a potent and selective IKK2 inhibitor showing good efficacy in a rat model of neutrophil activation.
Organizational Affiliation: 
GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK. john.2.liddle@gsk.com